IL1B and inflammatory bowel disease: As compounds 3 and 4, which are ichangensin-type limonoids, participated in the downregulation of IL-1β (71.2% and 83.8% at the high concentration of 100 μM), they might serve as therapeutic candidates for the treatment of IBD.